Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis
P. Canales-Herrerias, M. Uzzan, A. Seki…·S. Mehandru
This study investigates the mechanism of vedolizumab in ulcerative colitis by analyzing immune cell changes in gut-associated lymphoid tissue and shows that targeting GALT is a novel mechanism of action.